Charlotte Abson

Charlotte Abson

Auto-generated profile, based on publicly available information

Charlotte Abson

Department of Medical Oncology, Medway Hospitals NHS Trust, Medway Hospital, Gillingham, Kent ME7 5NY, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sidrah ShahSidrah Shah
Sidrah Shah
MKMikolaj Kutka
Mikolaj Kutka
KLKathryn Lees
Kathryn Lees
CACharlotte Abson
Charlotte Abson
MHMaher HADAKI
Maher HADAKI
Stergios BoussiosStergios Boussios
Stergios Boussios
Introduction: Malignant spinal cord compression (MSCC) is one of the most devastating complications of cancer. This event requires rapid decision-making on the part of several specialists, given the risk of permanent spinal cord injury or death. The goals of treatment in spinal metastases are pain control and improvement of neurological function. There can be challenges in delivering prompt diagnosis and treatment in a secondary care setting. We have reflected on the experience of managing MSCC in a district general setting. Aim: Our retrospective audit identified 53 patients with suspected MSCC who entered the relevant pathway from April 2017 to March 2018 at Medway, United Kingdom (UK). Our audit standards were set out by Medway Maritime Hospital and Maidstone and Tunbridge Wells NHS Trust MSCC working group members, using a combination of published evidence and best practice. Results: The patients with suspected MSCC were 53 and 29 of them (54.7%) had confirmed MSCC. The most common malignancies within the confirmed MSCC were lung (11 patients, 37.9%), breast (5 patients 17.2%), and renal (3 patients, 10.3%), followed by prostate, myeloma and carcinoma of unknown primary (2 patients (6.9%) each), as well as pancreatic, colorectal, lymphoma and, bladder (1 patient (3.4%) each). A magnetic resonance imaging (MRI) scan was performed in 48 patients (90.5%); the majority (31 patients, 64.6%) underwent the MRI within the first 24 h, whereas 3 patients had the investigation between 24 and 72 h from the admission. Among the 29 patients with confirmed MSCC, 6 (20.6%) were treated with surgical decompression, while 20 (69%) received radiotherapy (RT) and 3 (10.3%) best supportive care, respectively. Median time to surgery was 5 days (ranged between 2 and 8 days), whereas for RT 44.4 h (ranged between 24 and 72 h). Finally, all 3 patients that decided on symptom control were referred to a palliative care team within the first 24 h following the MRI scan. Conclusions: MSCC is frequently presented outside tertiary care. This may cause subsequent delays in investigation, diagnosis, and treatment, which can be improved by following a fast track referral pathway.

15 February 2021 in Cancer Research
Verified
Journal Article
Closed access
SRSimon N Rodney
Simon N Rodney
CACharlotte Abson
Charlotte Abson
RBRussell Burcombe
Russell Burcombe
RJRema Jyothirmayi
Rema Jyothirmayi
CHCatherine Harper-Wynne
Catherine Harper-Wynne
Background: The global COVID-19 pandemic has placed unprecedented burden on individual oncology patients, oncology departments, hospitals and national health systems. In order to protect individual patients from the risk of COVID-19 infection as well as improve capacity for COVID-19 patient management, a series of national and internationally agreed measures were proposed. During the first wave of infections the virulence and effect on cancer patients was not known. It is vitally important that the measures implemented to combat these risks are assessed and evaluated in order to learn best how to manage potential future waves of known and unknown viral infections.Methods: The international ESMO COVID-19 guidelines and national (NICE) guidelines were implemented across Kent, UK. All changes to treatment regimens were audited to assess what were the most frequent changes and in which patient groups could these be implemented. Data was subdivided for both early and advanced breast cancer as well as ER+, HER2+ or triple negative disease.Results: We collected full treatment history from 1,718 breast cancer patients currently receiving active oncology treatments. We were able to change treatment regimens due to COVID19 for 32.8% of patients. Of these 27.1% were early breast cancer patients compared with 43.7% were those with advanced metastatic disease. The most common changes for neoadjuvant changes were proceeding to surgery before completion of planned chemotherapy (10.2%), switch to 3 weekly Paclitaxel (10%) and chemotherapy break (8%). For adjuvant patients the most common changes included postponement of bisphosphonates (70.8%), chemotherapy break (13.5%), and curtailment to 6 months of adjuvant Trastuzumab (10.4%). For our palliative patients the most common changes included delay CDK4/6 inhibitor treatment (79.2%), postponement of bisphosphonates (24.8%), break in HER2 antibody (9.6%) and break in chemotherapy (8%).Conclusions: A large proportion of breast cancer oncology patients were deemed suitable to have a change in original planned treatment. We are fortunate to have comparatively large number of treatment options that can be customised on a patient basis to individual reduce risk of COVID-19. Further analysis is needed over time to compare the oncological outcomes of those in whom treatment was changes from the current gold standards of care. Citation Format: Simon N Rodney, Charlotte Abson, Russell Burcombe, Rema Jyothirmayi, Catherine Harper-Wynne. Changes in management of breast cancer patients during first wave of COVID19, throughout the area of Kent, United Kingdom. An audit of ESMO guideline implementation [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-06.

17 March 2022 in World Academy of Sciences Journal
Verified
Journal Article
Open access
PDF file
BPB. Srinivas Pedamallu
B. Srinivas Pedamallu
DHDelilah Hassanally
Delilah Hassanally
AKAbdul Kasem
Abdul Kasem
CACharlotte Abson
Charlotte Abson
IAIbrahim Ahmed
Ibrahim Ahmed
The ideal time to surgery interval in breast cancer patients following neoadjuvant chemotherapy according to published literature is as low as 21 days, 40 days and up to 8 weeks. The authors' hospital multidisciplinary team (MDT) accepted 28 days as a reasonable time interval to allow recovery from the side‑effects of neoadjuvant chemotherapy. The present retrospective clinical audit presents a review of all breast cancer cases that received neoadjuvant chemotherapy and examined the conformity to the set audit standards. The primary aim of the present audit was to investigate the time interval from the conclusion of neoadjuvant chemotherapy to surgery in breast cancer patients, and to determine the causes of potential delays and identifying means to improve the outcomes of the current process. The secondary objectives were to investigate the timing of tumour coil insertion, the timing of surgical planning multidisciplinary team meeting, the time to addition to the surgical waiting list and whether these patients had adequate tumour monitoring for effective surgical planning. A total of 59 breast cancer patients who had received neoadjuvant chemotherapy from November 1, 2011 to October 31, 2016 were identified. In total, one primary audit standard and six secondary audit standards were derived from the MDT consensus agreement and reasons for non‑conformity to these standards were audited. The primary standard was described as ‘surgery should be performed within 28 days of completion of last cycle of neoadjuvant chemotherapy’. The results revealed that conformity to this standard was 14%. The conformity of secondary standards was also poor, ranging from 20 to 98%. The results of the present audit were not very encouraging. Recommendations were drawn with a plan for a re‑audit following the implementation of changes agreed upon by the multidisciplinary team and a plan of action was prepared. It was concluded that achieving a time to surgery interval of <28 days following the completion of neoadjuvant chemotherapy is an achievable challenging task and only possible with an efficient multidisciplinary team work.